Further studies in this area should address if other missense mutations in FANCJ (linked to FA or associated with breast or ovarian cancer) that specifically interfere with key protein interactions of FANCJ but leave the catalytic function intact are able to differentially function in ICL repair versus response to agents that impede but do not entirely arrest cellular DNA replication. The gene discussed is BRIP1; the disease is ovarian cancer.